Drugs / N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
also known as
BCTC
targets TRPV1 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07092215 | Jun → Jul 2025 | — | Stefan Heber | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide | “BCTC (N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide) This TRPV1 antagonist is administered at a total dose of 2 x 0.34 µg = 0.68 µg and added to the...” NCT07092215 ↗ |
| Known as | BCTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07092215 ↗ |
| Action | Inhibit | “This TRPV1 antagonist” NCT07092215 ↗ |
| Target | TRPV1 | “This TRPV1 antagonist” NCT07092215 ↗ |